✦ LIBER ✦

P.279 A randomised trial of pegylated interferon alpha-2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin

✍ Scribed by A. Ciancio; A. Picciotto; C. Giordanino; A. Smedile; M. Tabone; A. Manca; G. Marenco; P. Garbagnoli; M. Andreoni; G. Cariti; G. Calleri; M. Sartori; S. Cusumano; A. Grasso; M. Basso; M. Rizzetto; G. Saracco

Book ID: 117770496
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 138 KB
Volume: 36
Category: Article
ISSN: 1386-6532
DOI: 10.1016/s1386-6532(06)80459-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized trial of pegylated-interfer

A randomized trial of pegylated-interferon-α2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin

✍ A. CIANCIO; A. PICCIOTTO; C. GIORDANINO; A. SMEDILE; M. TABONE; A. MANCA; G. MAR 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 464 KB

Controlled trial with pegylated interfer

Controlled trial with pegylated interferon-alpha2b plus ribavirin retreatment in patients with chronic hepatitis C not responding to a previous antiviral treatment with standard interferons combined with ribavirin

✍ G. Teuber; B. Kallinowski; C. Niederau; H. Klinker; P.R. Galle; M. Zankel; S. Ze 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 163 KB

Clinical trial: a randomized trial of pe

Clinical trial: a randomized trial of pegylated-interferon-α-2a plus ribavirin with or without amantadine in treatment-naïve or relapsing chronic hepatitis C patients

✍ P. LANGLET; F. D’HEYGERE; J. HENRION; M. ADLER; J. DELWAIDE; H. VAN VLIERBERGHE; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB

A randomized controlled trial of pegylat

A randomized controlled trial of pegylated interferon α-2a (40 KD) or interferon α-2a plus ribavirin and amantadine vs interferon α-2a and ribavirin in treatment-naïve patients with chronic hepatitis C

✍ A. Mangia; G. L. Ricci; M. Persico; N. Minerva; V. Carretta; D. Bacca; M. Cela; 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB

P.275 Influence of genotype, viral load

P.275 Influence of genotype, viral load and fibrosis on the sustained virologic response rate to pegylated interferon alpha-2a plus ribavirin, with or without amantadine, in chronic hepatitis C patients non-responders to alpha interferferon plus ribavirin

✍ H. Cheinquer; M. Pessoa; H. Sette Jr.; E. Parise; R. Paraná; F. Tatsch 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 147 KB

Neutralizing antibodies to interferon-α

Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy*)

✍ Philippe Halfon; Sophie Pérusat; Marc Bourlière; Jean-Pierre Bronowicki; Pascale 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

## Abstract A lack of antiviral response in patients with chronic hepatitis C treated with pegylated (PEG)‐interferon (IFN)‐α‐2a + ribavirin (RIBA) may be explained by neutralizing antibodies to IFN‐α‐2a. The aim of this study was to assess neutralizing antibodies to IFN‐α‐2a and IFN levels in non‐